Cleveland Biolabs Inc. Protectan CBLB502 Demonstrates Strong Mitigation Of Hematopoietic Damage at 48 Hours Post-Exposure to 6.5 Gy of Radiation

BUFFALO, NY--(Marketwire - March 31, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that recent primate studies have demonstrated the efficacy of Cleveland BioLabs’s Protectan CBLB502 as a mitigator of hematopoietic damage up to 48 hours post radiation exposure.